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AbstrAct
Background Off- label use (OLU) of a drug reflects a 
perceived unmet medical need, which is common in 
oncology. Cancer drugs are often highly expensive and 
their reimbursement is a challenge for many healthcare 
systems. OLU is frequently regulated by reimbursement 
restrictions. For evidence- based healthcare, treatment 
ought to be reimbursed if there is sufficient clinical 
evidence for treatment benefit independently of patient 
factors not related to the treatment indication. However, 
little is known about the reality of OLU reimbursement and 
its association with the underlying clinical evidence. Here, 
we aim to investigate the relationship of reimbursement 
decisions with the underlying clinical evidence.
Methods/ design We will extract patient characteristics 
and details on treatment and reimbursement of cancer 
drugs from over 3000 patients treated in three Swiss 
hospitals. We will systematically search for clinical trial 
evidence on benefits associated with OLU in the most 
common indications. We will describe the prevalence 
of OLU in Switzerland and its reimbursement in cancer 
care, and use multivariable logistic regression techniques 
to investigate the association of approval/rejection of a 
reimbursement requests to the evidence on treatment 
effects and to further factors, including type of drug, 
molecular predictive markers and the health insurer.
Discussion Our study will provide a systematic overview 
and assessment of OLU and its reimbursement reality in 
Switzerland. We may provide a better understanding of the 
access to cancer care that is regulated by health insurers 
and we hope to identify factors that determine the level of 
evidence- based cancer care in a highly diverse western 
healthcare system.
BaCkgrounD
Drugs prescribed in routine medical care 
typically require licensing and approval for 
defined indications by health authorities, 
for example the US Food and Drug Admin-
istration (FDA), the European Medicines 
Agency (EMA) or Swissmedic (SM) in Swit-
zerland. Indications usually contain restric-
tions in drug usage to a disease in a certain 
setting, line of treatment and cotreatment 
with another drug. Off- label use (OLU) 
means using the drug outside the approved 
indication. In particular in cancer therapy, 
where new agents emerge frequently, OLU 
is common practice.1 International estimates 
range from 13% to 71% of adults receiving 
off- label therapy during cancer treatment,1 
with about 30% in Switzerland.2 When 
new evidence for clinical benefit of a drug 
emerges, OLU allows usage before the indi-
cation is formally approved and labelled.3 
One example is the human epidermal growth 
factor receptor 2 (HER2)- directed agent tras-
tuzumab, which is approved standard treat-
ment for patients with HER2- positive breast 
cancer.4 5 Success of trastuzumab in HER2- 
positive breast cancer suggested benefits for 
other HER2- overexpressing or amplifying 
tumours as well, for example gastric cancer. 
Indeed, in 2010 a randomised controlled trial 
(RCT) showed better survival for patients 
with advanced gastric cancer overexpressing 
HER2.6 However, it took another year until a 
formal approval for this new indication was 
granted by the FDA and in the meantime, 
patients could only receive this promising 
treatment via OLU. But counterexamples 
exist. Drugs being approved in certain cancer 
indications may not work in others, as shown 
for irinotecan and bevacizumab in colorectal 
cancer. Both drugs are effective and approved 
in the metastatic setting7 8; however, in the 
adjuvant setting, no benefit was found9 10 ; 
such example emphasises that OLU may do 
harm to patients.
OLU is frequently regulated by reimburse-
ment restrictions, because cancer drugs 
are often highly expensive and their reim-
bursement is a challenge for many health-
care systems. This may reduce costs, but to 
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Figure 1 Flowchart for patient screening and eligibility 
criteria.
allow evidence- based healthcare, reimbursement should 
primarily be based on evidence. The Swiss healthcare 
system is highly diverse. Across the 26 cantons with 
diverse care structures and local regulation, there are 57 
statutory health insurers (as of October 2018).11 They 
base their reimbursement policies on decisions of the 
Swiss Federal Office of Public Health (FOPH), which 
determines the drugs and indications that have to be 
reimbursed. For intended OLU, an upfront request for 
reimbursement to the patient’s health insurer is manda-
tory. These reimbursement requests are then appraised 
by reviewers (medical examiners) commissioned by the 
statutory health insurers, who give recommendations on 
acceptance of the request with subsequent access to that 
treatment. They may use various tools12 to guide their 
decisions on whether to approve or disapprove the reim-
bursement for OLU and are supposed to consider the 
available clinical evidence but also the individual clinical 
circumstances and patient characteristics.
Although these tools are recommended, it is neither 
mandatory nor transparent how they would be applied. 
There is no structured and transparent systematic frame-
work specifically regulating the case- by- case decisions. 
There is also no empirical information on the reimburse-
ment reality, which would be a prerequisite for quality 
control and potential improvement of this approach. 
Overall, due to the high costs of oncology drugs, access 
of Swiss patients to drugs used in off- label indications is 
currently based on intransparent processes.
Here, we describe the rationale and design of the OLU- 
Cancer project as part of the Comparative Effectiveness 
of Innovative Treatments (CEIT) project.13 The CEIT 
project evaluates the generation of clinical trial evidence 
for novel drug treatments, in the case of OLU using a 
large sample of patients to provide empirical evidence 
on access to OLU in a highly diverse western healthcare 
system.
MethoDs
Our main objective is to investigate the relationship of 
reimbursement decisions to the underlying clinical 
evidence on patient benefits and subsequent access to 
cancer drugs. We also aim to assess the role of further 
factors that may influence the reimbursement. Finally, we 
aim to describe the prevalence of OLU and its reimburse-
ment in patients with cancer within the Swiss healthcare 
system.
The project is organised in three phases: First, we iden-
tify, extract and classify the data on OLU from patient 
records (electronic and paper- based). Secondly, we deter-
mine the clinical evidence using rapid review techniques, 
standard approaches for evidence synthesis and review- of- 
review methods. Finally, we combine the results of both 
phases to address our research objectives.
reimbursement reality
Eligibility criteria
We will screen patient records for reimbursement 
requests at three collaborating major hospitals, all 
being tertiary referral centres: University Hospital Basel 
(Department of Medical Oncology and Department of 
Haematology), University Hospital Bern (Department of 
Medical Oncology) and a large general district hospital 
in St. Gallen (Department of Oncology/Haematology).
We will screen all patients who had their first consul-
tation between January 2015 and July 2018. Patients are 
eligible if they have a malignant disease (solid or haema-
tological) and receive systemic anticancer treatment 
with a drug or biologic. Patients with at least one reim-
bursement request issued by the treating physician will 
be included in data extraction (see figure 1). We exclude 
patients who have only a one- time appointment for a 
second opinion, whose disease is not treated with drugs 
but surgery or radiotherapy only, or for whom no reim-
bursement request was issued.
Sample size considerations
Based on a previous study on OLU in Switzerland,2 we 
assume that at least one reimbursement request for 
OLU has been issued for around 20% to 30% of eligible 
patients. In addition, preliminary data from the three 
sites revealed a proportion of 20% OLU. To account for 
the uncertainty on the actual frequency of OLU requests 
(both approved and disapproved), we consider a range 
of plausible proportions (15%, 20% and 25%) of OLU 
among all patients. To achieve a high precision of esti-
mates, we plan to screen around 3000 eligible patients. 
This would result in the following frequencies and 
proportions with 95% CIs for OLU per patient:
 ► 450/3000 (15%, 95% CI: 13.8% to 16.3%)
 ► 600/3000 (20%, 95% CI: 18.6% to 21.5%)
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Table 1 Categorisation of drug use depending on licence and labe.
Category FDA or EMA licensed Swissmedic licensed Agreement with Swissmedic label
Compassionate use No No –
Unlicensed use Yes No –
OLU Yes Yes No
On- label Yes Yes Yes
EMA, European Medicines Agency; FDA, Food and Drug Administration; OLU, off- label use.
 ► 900/3000 (30%, 95% CI: 28.4% to 31.7%)
We find all of them acceptable. To determine the actual 
proportion of disapproved reimbursement requests for 
OLU is a central objective of this project, however, based 
on preliminary data from this project and data from a 
single department that has implemented monitoring of 
its reimbursement requests since 2017, we assume that 
around 30% of OLU requests are disapproved. Consid-
ering the above- mentioned range of plausible frequen-
cies of OLU requests, this would result in the following 
frequencies and proportions with 95% CIs for disap-
provals per OLU request:
 ► 135/450 (30%, 95% CI 25.8% to 34.5%)
 ► 180/600 (30%, 95% CI 26.4% to 33.9%)
 ► 270/900 (30%, 95% CI 27.0% to 33.1%)
Thus, we consider a sample of 3000 eligible patients as 
sufficient to determine the prevalence of OLU, the prev-
alence of disapproved OLU and also for our planned 
multivariable regression modelling (see Contrasting 
evidence to reimbursement reality section).
Extraction of patient-related health and reimbursement data
To assess the prevalence of OLU requests, we will screen 
patient records of all eligible patients for any reimburse-
ment request. For those patients, we will extract patient 
demographics, disease and treatment details, and infor-
mation on reimbursement requests and correspondence 
with the respective health insurer. This information will 
be stored in a relational database that we generated for 
this purpose. Details of the collected variables are avail-
able below (online supplementary table S1).
Definition and categorisation of OLU
We will define OLU as any drug use that does not agree 
with the SM drug label. We will also assess unlicensed use 
(drug marketing is not licensed by SM for Switzerland, 
but approved by the FDA or EMA) and compassionate use 
(drug is neither licensed by the FDA, EMA nor SM) (see 
table 1). We will further subcategorise OLU according to 
disease, intended treatment setting (eg, adjuvant), line of 
treatment (eg, first line) and use as single agent or drug 
combination. This allows us to investigate the prevalence 
of OLU in different situations.
Timeline of licensing and approval
Licensing of a cancer drug often starts with a single indica-
tion and, over time, additional indications are approved. 
Drug labels, on- label and off- label status may change over 
time. We will systematically record the approval dates of 
all requested drugs for each disease and new indication 
in a structured database. We will identify these dates by 
searching for publications and press releases of SM and 
the FOPH to develop a timeline for each drug and its 
label changes.
Two trained oncologists/haematologists will inde-
pendently determine the OLU status for each request at 
the time of the request. Disagreements will be solved by 
discussion. Because the off- label status is time- dependent, 
we will match the date of the OLU request with the 
approval timeline of the respective drug label.
OLU prevalence
We will estimate the prevalence of OLU and the frequency 
of reimbursement. Specifically, we will investigate:
 ► The frequency and proportion of all reimbursement 
requests among all eligible patients treated for a 
malignant disease.
 – The frequencies and proportions of OLU, compas-
sionate and unlicensed use among all reimburse-
ment requests.
 – Frequencies and proportions of OLU requests for 
certain types of anti- cancer drugs, stratified by their 
approval date.
 – Frequency and proportion of OLU requests for a 
drug targeting a molecular predictive marker irre-
spective of tumour site of origin.
 ► Frequency and proportion of approval/rejection 
among all reimbursement requests for OLU, unli-
censed and compassionate use.
 – Frequency and proportion of how costs for re-
quested drugs are covered stratified by approval/
rejection.
 – Frequency and proportion of rebuttals to rejec-
tions among all reimbursement requests for OLU, 
unlicensed and compassionate use.
 – Frequency of how many decisions were changed 
from rejection to approval by rebuttal of the treat-
ing physician.
 ► The time between reimbursement request and 
approval/disapproval of reimbursement decision.
Unit of calculation is the individual request. We will 
re- evaluate all these factors in subgroups of requests clus-
tered by the patient’s health insurer (insurer as per index 
date of first reimbursement request).
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Clinical evidence
We will systematically evaluate the evidence for treatment 
effects on overall survival (OS) and progression- free 
survival (PFS) in OLU situations.
Literature search
For the most common off- label indications, we will generate 
overarching clinical questions following the PICO struc-
ture,14 composed of population (disease, treatment setting, 
treatment line), intervention (drug, single agent or combi-
nation), control (any comparator) and outcome (PFS or 
OS). Most common OLU indications and resulting PICO 
questions will be derived from the extracted patient data 
(for details, see online supplementary table S1).
We will use rapid review techniques to identify system-
atic reviews (SRs) of RCTs addressing these questions. 
If there are no eligible SRs available, we will directly 
search for RCTs. We will search PubMed and use perti-
nent keywords and subject headings for cancer sites and 
generic drug terms. Standard search filters for SRs and 
RCTs will be used.15 In general, we will include publica-
tions reporting treatment effects on PFS and OS that are 
published in English or German. No further limits will be 
applied. Further evidence will be sought by backward cita-
tion chasing16 (screening the reference lists of included 
publications). Search strategies will be created by an 
information specialist and will be peer- reviewed.
We will additionally evaluate literature provided by the 
requesting physician and consult guidelines provided by 
the European Society of Medical Oncology and verify if our 
search identifies any RCTs not found in our systematic liter-
ature searches.17
Study selection and data extraction
Overall, for feasibility and efficiency reasons, we will use 
the SRs primarily to identify pertinent RCTs and their 
results. In a first step, we will select the most recent SR 
publication identified in the SR search that is covering 
the PICO. We will always prefer a recent Cochrane 
Review due to the comparatively high methodological 
quality and standardised and transparent reporting. We 
only consider SRs that are sufficiently transparent in 
reporting key methods. This means, we include only SRs 
that adequately report the PRISMA (Preferred Reporting 
Items for Systematic Reviews and Meta- Analyses) items 
‘identification’, ‘screening’, ‘eligibility’, ‘included’.18 
We deem reporting adequate if it would let us replicate 
the search for RCTs. Selection of SRs will be done inde-
pendently by two reviewers and confirmed by a third 
reviewer in case of uncertainty.
In a second step, we will identify the pertinent RCTs 
included in eligible SRs. From each eligible SR article, 
we extract bibliographic details of the SR, search details 
(search date, databases) and any RCT and corresponding 
publication matching our PICO of interest. From each 
pertinent RCT article, we extract bibliographic infor-
mation and the date of publication (earliest available: 
online or printed if printed publication was available 
before published online). We will extract the treatment 
effects directly from the RCT publication, based on the 
main analysis of the intention- to- treat population, where 
available. The rationale behind this is that we want to 
depict the evidence as it was at the time of request. In 
case of multiple reported effect estimates, we prefer that 
one clearly labelled as prespecified, main analysis or first 
reported in the abstract (acknowledging possible spin by 
relying on prominently reported results for consistency, 
which will be addressed in sensitivity analyses).
If no appropriate SR can be identified, we will apply the 
same procedure to the RCT search.
Evidence synthesis and overview
We will synthesise the evidence by using cumulative meta- 
analysis techniques.19 20 We will combine all trials on the 
same PICO question and determine for the time point, 
when new evidence is available, the current knowledge 
on clinical benefits (ie, the summary treatment effect esti-
mate for OS and PFS from all RCTs up to that point). This 
allows us to describe the evolution of clinical knowledge 
from RCTs in any oncological off- label indication with 
clinical trial evidence over time.
We will categorise the available evidence on patient- 
relevant treatment benefits from RCTs (summary treat-
ment effect from meta- analyses) for each drug and 
indication into:
1. The combined analysis shows OS benefit (nominal sta-
tistical significance).
2. The combined analysis shows PFS benefit (nominal 
statistical significance), but no OS benefit.
3. No indication for benefit or harm (no nominal statisti-
cally significant OS or PFS effect).
4. Inconclusive (nominal statistical treatment benefit for 
OS but significant harm for PFS or vice versa).
5. The combined analysis shows OS harm.
6. The combined analysis shows PFS harm.
7. Unclear (no randomised trial evidence available).
Contrasting evidence to reimbursement reality
Finally, we will investigate the association between the 
reimbursement decision for OLU and clinical evidence 
using multilevel multivariable logistic regression. Further-
more, we aim to identify other factors than clinical 
evidence explaining any potential discrepancies between 
clinical evidence and reimbursement.
Association of reimbursement to evidence
We will use multilevel multivariable logistic regression to 
investigate the association between the clinical evidence 
supporting OLU and the likelihood for reimbursement 
of OLU. We have chosen multilevel modelling, because 
requests are clustered by patients and health insurers. We 
will condense the seven categories of clinical evidence 
into three groups (A–C) and summarise treatment bene-
fits:
A. Clear patient- relevant benefit (corresponds to catego-
ry 1).
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B. Potential patient- relevant benefit (corresponds to cat-
egory 2).
C. No proven patient- relevant benefit (corresponds to 
category 3–7).
We will determine the category for the time when each 
reimbursement was requested. Category A will be the 
reference for this categorical variable, which is the inde-
pendent variable in the regression analysis. Rejection of a 
request for reimbursement of OLU will be the dependent 
binary variable (rejected vs approved). The association 
will be expressed as ORs with 95% CIs, with an OR >1 
indicating a higher likelihood for the reimbursement to 
be rejected by the health insurer. We hypothesise that the 
risk for rejection will be higher in situations of category C 
than B and higher for category B than A.
The above- mentioned consideration of time points in 
our data collection and analysis will allow us to investigate 
potential time lags between occurrence of new evidence 
for treatment benefit and SM approval/labelling. In 
such periods, patients can only access new drugs through 
OLU reimbursement by the health insurer or extended 
access programmes by the respective drug manufacturer. 
However, the latter is completely at the discretion of the 
drug manufacturer; therefore, requesting OLU from the 
health insurer is often the only way to receive the drug. 
We will therefore additionally investigate the following:
 ► The time lag between availability of evidence for 
treatment benefit (category A or B) and approval 
of the drug by SM. This time will be calculated from 
the earliest date of trial publication to the date of 
approval by SM.
 ► The number of cases in this time period, for each 
indication, in which an OLU request was issued and 
the number of these requests rejected for reimburse-
ment, although evidence for treatment benefit (cate-
gory A or B) was available.
Association of reimbursement to other factors
To investigate whether patient or disease characteristics 
that are not related to the treatment indication influence 
the risk for rejection of request for OLU reimbursement, 
we will perform multilevel multivariable logistic regres-
sion analysis including seven variables. These variables 
are the following:
1. Sex (categorical variable: male vs female).
2. Age (continuous variable).
3. Presence of molecular predictive marker (binary vari-
able; we anticipate that presence of a marker lowers 
the risk of rejection because of the availability of a drug 
target independent of the disease).
4. Disease type (categorical variable: solid vs haemato-
logical malignancies; we anticipate that chances for 
reimbursement are higher for haematological malig-
nancies because there are often only OLU treatment 
options available for haematological malignancies).
5. Type of drug (categorical variable: immunotherapy 
(checkpoint inhibition) vs all others; we anticipate 
that chances for reimbursement are higher for immu-
notherapy because this drug class has recently been 
approved for several tumour entities).
6. Orphan drug status (binary variable; we anticipate that 
chances for reimbursement are higher for an orphan 
drug/indication because there are less treatment op-
tions available).
7. Tumour incidence (continuous variable; we antici-
pate that chances for reimbursement are higher for 
rare diseases because there are less treatment options 
available).
We assume that there is less evidence for rare diseases. 
However, such patients may often be particularly in need 
for OLU. We will rank the entities by incidence according 
to global cancer statistics as issued by the WHO21 and 
label orphan drugs according to SM.22 For sensitivity 
analyses, we will consider the orphan drug designation as 
used by the FDA.23
handling of missing data
We will report frequencies (proportions) of missing data 
of all independent and dependent variables. The primary 
analysis will be based on complete cases, but we will use 
multiple imputations for missing data for a sensitivity 
analysis using all cases.24
software
We will use Ninox (https:// ninoxdb. de/ de/) for 
managing data and generating relational databases, R for 
data cleaning and most statistical analyses (The R Project 
for Statistical Computing, https://www. r- project. org/) 
and Stata (StataCorp. 2017. Stata Statistical Software: 
Release 15, College Station, Texas, USA) for multilevel 
regression modelling.
DisCussion
This study will provide a comprehensive assessment of 
OLU and its reimbursement reality in Switzerland, a 
systematic overview of the comparative effectiveness of 
OLU in cancer care and a thorough investigation on the 
association between OLU reimbursement and the under-
lying evidence from clinical research. By publishing this 
rationale and design paper, we intend to minimise ambi-
guity and increase transparency concerning our study.25
To our knowledge, this will be the first study targeting 
OLU in such extent and level of detail. We will use trans-
parent sources and apply systematic and reproducible 
search strategies. The collaboration with four haema-
tology/oncology departments across Switzerland will 
provide us with a sufficient number of patients to gain a 
representative sample for our planned investigations.
We will highly depend on the comprehensiveness of 
documentation in patient files, but we expect that the docu-
mentation of correspondence with the health insurer will 
at least be routinely included in the patient files due to the 
substantial economic and administrative impact.
This study will provide a comprehensive overview on 
access to off- label treatments in a highly developed country, 
characterised by a fragmented and expensive healthcare 
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system. It will help to determine if access to perceived 
unmet medical needs is based on clinical evidence and if 
the Swiss healthcare system employs principles of evidence- 
based healthcare for OLU. We hope to reveal potential 
inequalities in access, to better understand and ultimately 
improve the quality of reimbursement decisions for patients 
with cancer. To put our results in context, we plan to install 
a multidisciplinary, international scientific advisory board 
including important stakeholders to optimally disseminate 
and implement the findings of this study.
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